Risk of Cancer in Patients Receiving Non-biologic Disease-modifying Therapy for Rheumatoid Arthritis Compared with the UK General Population

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2012 Dec 15

PMID 23238979

Citations 49

Authors

Louise K Mercer

Rebecca Davies

James B Galloway

Audrey Low

Mark Lunt

William G Dixon

Kath D Watson

Deborah P M Symmons

Kimme L Hyrich

Affiliations

Soon will be listed here.

Abstract

Objectives: To quantify the risk of cancer and compare it with that for the general population in a modern cohort of UK patients with RA and to identify risk factors for cancer among this cohort.

Methods: The study population comprised biologic-naïve RA subjects receiving non-biologic disease-modifying therapy recruited to the British Society for Rheumatology Biologics Register from 2002 to 2009. Standardized incidence ratios (SIRs) for cancers were calculated using age- and gender-specific cancer rates in the English population. Poisson regression models adjusted for age and gender using England general population data were used to determine the association of other predictors with incident malignancy.

Results: The cohort comprised 3771 individuals with RA contributing 13 315 person-years of follow-up. One hundred and eighty-two cancers were reported: 156 solid and 26 myelo- or lymphoproliferative cancers. The overall SIR was 1.28 (95% CI 1.10, 1.48). Risks of lung cancer (SIR 2.39, 95% CI 1.75, 3.19), Hodgkin lymphoma (SIR 12.82, 95% CI 4.16, 29.92) and non-Hodgkin lymphoma (SIR 3.12, 95% CI 1.79, 5.07) were higher compared with the general population and risks of prostate cancer (SIR 0.35, 95% CI 0.11, 0.82) and cancers of the female genital organs (SIR 0.35, 95% CI 0.10, 0.90) were reduced. Within the cohort, cancer risk was more than 2-fold higher in current or ex-smokers than in non-smokers.

Conclusion: The overall incidence of cancer was increased in this national cohort of subjects with RA. The association of RA with certain cancers needs to be considered when studying the effects of biologic therapy, such as anti-TNF, on cancer risk.

Citing Articles

Epidemiology of Sjögren syndrome.

Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R Nat Rev Rheumatol. 2023; 20(3):158-169.

PMID: 38110617 DOI: 10.1038/s41584-023-01057-6.

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.

Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R Lancet Reg Health Eur. 2023; 35:100768.

PMID: 37954220 PMC: 10637983. DOI: 10.1016/j.lanepe.2023.100768.

Dos and don'ts in designing a computerized oral and lip squamous cell cancer registry.

Shahmoradi L, Mahdavi N, Saffar H, Ghalehtaki R, Shirkhoda M, Motiee-Langroudi M BMC Health Serv Res. 2023; 23(1):1010.

PMID: 37726768 PMC: 10510180. DOI: 10.1186/s12913-023-09860-3.

Causal inference between rheumatoid arthritis and prostate cancer.

Ou J, Zou L, Wu Y, Zhang Q, Fang Y, Qiu M Clin Exp Med. 2023; 23(8):4681-4694.

PMID: 37567983 DOI: 10.1007/s10238-023-01151-9.

Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.

Tanaka K, Ichikawa A, Umezawa N, Yamamoto K, Yoshifuji K, Okada K Cancer Sci. 2023; 114(9):3719-3727.

PMID: 37365854 PMC: 10475769. DOI: 10.1111/cas.15894.

References

Flossmann E, Rothwell P . Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369(9573):1603-13. DOI: 10.1016/S0140-6736(07)60747-8. View

Habel L, Zhao W, Stanford J . Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 2002; 13(5):427-34. DOI: 10.1023/a:1015788502099. View

Prizment A, Folsom A, Anderson K . Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):435-42. PMC: 2820129. DOI: 10.1158/1055-9965.EPI-09-0976. View

Takkouche B, Regueira-Mendez C, Etminan M . Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008; 100(20):1439-47. DOI: 10.1093/jnci/djn324. View

Fairchild W, Spence C, Solomon H, Gangai M . The incidence of bladder cancer after cyclophosphamide therapy. J Urol. 1979; 122(2):163-4. DOI: 10.1016/s0022-5347(17)56306-5. View

Glover M, Deeks J, Raftery M, Cunningham J, Leigh I . Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997; 349(9049):398. DOI: 10.1016/S0140-6736(97)80015-3. View

Salinas C, Kwon E, FitzGerald L, Feng Z, Nelson P, Ostrander E . Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010; 172(5):578-90. PMC: 2950822. DOI: 10.1093/aje/kwq175. View

Kirwan J, Reeback J . Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol. 1986; 25(2):206-9. DOI: 10.1093/rheumatology/25.2.206. View

Murad A, Down L, Davey Smith G, Donovan J, Lane J, Hamdy F . Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer. 2010; 128(6):1442-8. DOI: 10.1002/ijc.25465. View

10.

Luqmani R, Hennell S, Estrach C, Basher D, Birrell F, Bosworth A . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford). 2009; 48(4):436-9. DOI: 10.1093/rheumatology/ken450a. View

11.

Thomas E, Brewster D, Black R, Macfarlane G . Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000; 88(3):497-502. View

12.

Mattey D, Thomson W, Ollier W, Batley M, Davies P, Gough A . Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum. 2007; 56(5):1408-16. DOI: 10.1002/art.22527. View

13.

Parikh-Patel A, White R, Allen M, Cress R . Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009; 20(6):1001-10. PMC: 4354853. DOI: 10.1007/s10552-009-9298-y. View

14.

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):692-701. DOI: 10.1002/art.21675. View

15.

Symmons D, Harrison B . Early inflammatory polyarthritis: results from the norfolk arthritis register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis. Rheumatology (Oxford). 2000; 39(8):835-43. DOI: 10.1093/rheumatology/39.8.835. View

16.

Abasolo L, Judez E, Descalzo M, Gonzalez-Alvaro I, Jover J, Carmona L . Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2007; 37(6):388-97. DOI: 10.1016/j.semarthrit.2007.08.006. View

17.

Chen Y, Chang Y, Wang C, Wu C . The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011; 63(2):352-8. DOI: 10.1002/art.30134. View

18.

Brasky T, Velicer C, Kristal A, Peters U, Potter J, White E . Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev. 2010; 19(12):3185-8. PMC: 3005534. DOI: 10.1158/1055-9965.EPI-10-0942. View

19.

Gridley G, McLaughlin J, Ekbom A, Klareskog L, Adami H, Hacker D . Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993; 85(4):307-11. DOI: 10.1093/jnci/85.4.307. View

20.

Askling J, Fored C, Brandt L, Baecklund E, Bertilsson L, Feltelius N . Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64(10):1421-6. PMC: 1755244. DOI: 10.1136/ard.2004.033993. View